Cargando…
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome
BACKGROUND: The BCN02-trial combined therapeutic vaccination with a viral latency reversing agent (romidepsin, RMD) in HIV-1-infected individuals and included a monitored antiretroviral pause (MAP) as an efficacy read-out identifying individuals with an early or late (< or > 4weeks) viral-rebo...
Autores principales: | Oriol-Tordera, Bruna, Esteve-Codina, Anna, Berdasco, María, Rosás-Umbert, Míriam, Gonçalves, Elena, Duran-Castells, Clara, Català-Moll, Francesc, Llano, Anuska, Cedeño, Samandhy, Puertas, Maria C., Tolstrup, Martin, Søgaard, Ole S., Clotet, Bonaventura, Martínez-Picado, Javier, Hanke, Tomáš, Combadiere, Behazine, Paredes, Roger, Hartigan-O'Connor, Dennis, Esteller, Manel, Meulbroek, Michael, Calle, María Luz, Sanchez-Pla, Alex, Moltó, José, Mothe, Beatriz, Brander, Christian, Ruiz-Riol, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938861/ https://www.ncbi.nlm.nih.gov/pubmed/35325780 http://dx.doi.org/10.1016/j.ebiom.2022.103956 |
Ejemplares similares
-
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
por: Rosás-Umbert, Miriam, et al.
Publicado: (2020) -
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
por: Mothe, Beatriz, et al.
Publicado: (2020) -
Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control
por: Oriol-Tordera, Bruna, et al.
Publicado: (2020) -
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)
por: Mothe, Beatriz, et al.
Publicado: (2019) -
Does Antigen Glycosylation Impact the HIV-Specific T Cell Immunity?
por: Olvera, Alex, et al.
Publicado: (2021)